Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001259PREPARATION AND APPLICATION OF RECOMBINANT MULTIVALENT NOVEL CORONAVIRUS TRIMER PROTEIN VACCINE CAPABLE OF INDUCING BROAD-SPECTRUM AND NEUTRALIZING ACTIVITY
WO 26.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/107213 Applicant SINOCELLTECH LTD Inventor XIE, Liangzhi
A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.
2.102021013930DIAGNÓSTICO IMUNOLÓGICO DA COVID-19
BR 24.01.2023
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 102021013930 Applicant UNIVERSIDADE FEDERAL DE PELOTAS Inventor ANA VITÓRIA COSTA
DIAGNÓSTICO IMUNOLÓGICO DA COVID-19. A presente invenção enquadra-se na área de Biotecnologia e refere-se a um ensaio imunoabsorvente (ELISA) que detecta e mensura anticorpos IgG, IgM ou IgA anti-SARSCov-2, agente etiológico da COVID-19, para fins de diagnóstico clínico, estudos epidemiológicos, monitoramento vacinal e pesquisa/desenvolvimento tecnológico. Diferentemente da maioria dos testes sorológicos comerciais que utiliza uma proteína de SARS-Cov-2 como antígeno (S ou N), a presente invenção descreve a produção e uso em imunodiagnóstico de uma quimera recombinante composta por regiões imunodominantes das duas principais proteínas antigênicas de SARS-Cov-2, conferindo elevada sensibilidade e especificidade ao teste. Esta quimera antigênica é produzida em alta quantidade por Escherichia coli e apresenta elevada estabilidade. A otimização de todas as etapas e insumos usados no ELISA com um painel de 1000 soros nacionais possibilitou o desenvolvimento de um teste de elevada acurácia e reprodutibilidade.
3.WO/2023/287324INFLUENZA VIRUS-BASED ISOLATED RECOMBINANT VIRUS
WO 19.01.2023
Int.Class C12N 15/117
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
Appl.No PCT/RU2022/050173 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor RUDENKO, Larisa Georgievna
The present invention relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated nucleic acid encoding a recombinant polypeptide for increasing the titer of antibodies to influenza virus (variants), an influenza virus-based recombinant virus for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases, a pharmaceutical composition and a vaccine that include the above influenza virus-based recombinant virus, as well as their use for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases.
4.2023004912抗体誘導性ポリペプチド及びワクチン
JP 17.01.2023
Int.Class A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
Appl.No 2022095590 Applicant 国立大学法人金沢大学 Inventor 渡部 良広
【課題】対象におけるSARS-CoV-2感染の治療又は予防に有用な抗体誘導性ポリペプチド、及び当該抗体誘導性ポリペプチドを含むワクチンを提供する。
【解決手段】以下の(a)~(f)に記載のポリペプチド群から選択され、かつ、抗体誘導性を有する、ポリペプチド:
(a)配列番号1の336~361位、406~432位、又は446~480位の部位内の連続する7個以上のアミノ酸からなるポリペプチド;
(b)前記(a)に記載のいずれかのポリペプチドのアミノ酸配列と、80%以上の配列同一性を有するアミノ酸配列を有する、ポリペプチド;
(c)前記(a)又は(b)に記載のポリペプチドを部分配列として含み、配列番号1の前記部分配列以外の部位を含まない、ポリペプチド;
(d)配列番号1の1144~1161位又は1174~1202位の部位内の連続する10個以上のアミノ酸からなるポリペプチド;
(e)前記(d)に記載のいずれかのポリペプチドのアミノ酸配列と、80%以上の配列同一性を有するアミノ酸配列を有する、ポリペプチド;及び
(f)前記(d)又は(e)に記載のポリペプチドを部分配列として含み、配列番号1の前記部分配列以外の部位を含まない、ポリペプチド。
【選択図】なし
5.2021121139Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа
RU 16.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2021121139 Applicant Акционерное общество "БИОКАД" (RU) Inventor Руденко Лариса Георгиевна (RU)
6.WO/2023/283106DEOPTIMIZED SARS-COV-2 VARIANTS AND METHODS AND USES THEREOF
WO 12.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/035824 Applicant CODAGENIX INC. Inventor MUELLER, Steffen
Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.
7.WO/2023/280220S PROTEIN VARIANT OF CORONAVIRUS AND USE THEREOF
WO 12.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/104158 Applicant FUDAN UNIVERSITY Inventor LIN, Jinzhong
The present invention relates to an S protein variant, which does not contain a complete cytoplasmic tail domain compared to an S protein of a wild-type coronavirus. Further provided are a nucleic acid molecule encoding the S protein variant, and the use of the S protein variant and the nucleic acid molecule in the preparation of a vaccine.
8.WO/2023/282771CORONAVIRUS VACCINE COMPOSITION
WO 12.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/NZ2022/050092 Applicant COVID-19 VACCINE CORPORATION LIMITED Inventor FELDMAN, Robert Graham
The present disclosure relates to a multivalent vaccine composition characterised in that it elicits broad spectrum protection against at least one strain of coronavirus (such as a viral lineage, in particular SARS-Cov-2, more specifically selected from B.1.617. 2 [delta and/or kappa variants], B.1.1.7 and/or omicron), said vaccine comprising: a pool of T cell epitopes derived from at least one viral protein wherein the vaccine has a calculated world population HLA coverage of at least 95%, for example 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%. The disclosure also relates to constructs disclosed herein, methods or preparing same and use in treatment including prophylaxis.
9.WO/2023/283446METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL
WO 12.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/036553 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor GOULD, Stephen J.
Coronavirus egress is mediated by lysosomal exocytosis. It is demonstrated herein that the D614G mutation enhances Spike trafficking to lysosomes and the lysosomal accumulation of newly synthesized virus particles, augments Spike-mediated disruption of endomembrane homeostasis, and causes a 3-fold reduction in cell surface Spike expression. Moreover, it is shown that the D614G mutation is an intragenic suppressor of the 12 nucleotide-long furin cleavage site (FCS) insertion, restoring Spike trafficking to lysosomes and TMPRSS2-independent infectivity, both of which had been impaired by the prior FCS insertion mutation. This data identifies enhanced lysosomal sorting as the earliest known manifestation of the D614G mutation, have implications for virus evolution, immunity, and vaccine design, and support a lysosomal model of coronavirus biogenesis and entry.
10.WO/2023/283651PAN-HUMAN CORONAVIRUS VACCINES
WO 12.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/073577 Applicant MODERNATX, INC. Inventor STEWART-JONES, Guillaume
The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.